| Autor: |
Vargas Ahumada J; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., González Rueda SD; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Sinisterra Solís FA; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Pitalúa Cortés Q; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Torres Agredo LP; Nuclear Medicine Department, Universidad Autónoma de Bucaramanga, Bucaramanga 680002, Colombia., Miguel JR; Urological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Scavuzzo A; Urological Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Soldevilla-Gallardo I; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Álvarez Avitia MA; Medical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., Sobrevilla N; Medical Oncology Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico., García Pérez FO; Nuclear Medicine and Molecular Imaging Department, National Cancer Institute, Tlalpan, Mexico City 14080, Mexico. |
| Abstrakt: |
Neuroendocrine differentiation of prostate cancer (NEDPC) includes de novo presentation and secondary to epigenetic changes, referred as therapy-induced neuroendocrine prostate cancer (t-NEPC). Molecular imaging with prostate-specific membrane antigen (PSMA) and somatostatin analogues positron emission tomography (PET/CT) in NEDPC have not been validated. 18 F-FDG (fluorodeoxyglucose) PET/CT has numerous limitations in prostate cancer (PCa) and the utility in NEDPC has only been reported in a few series of cases. The objective of this study is to compare the lesions detection rate of the three radiotracers in metastatic t-NEPC patients. (1) Material and Methods: Retrospective evaluation of patients with prostate adenocarcinoma treated with androgen deprivation therapy, chemotherapy, a novel androgen receptor pathway inhibitor or a combination of them and a second tumour biopsy confirming t-NEPC was made. All patients underwent 18 F PSMA-1007, 18 F AlF-NOTA-Octreotide, and 18 F-FDG PET/CT. Evaluation of positive lesions was determined and SUVmax of each radiotracer was estimated and correlated with computer tomography (CT) findings. (2) Results: A total of eight patients were included. The mean time from diagnosis of prostate adenocarcinoma to t-NEPC was 28.2 months, with a mean serum specific prostate antigen (PSA) of 16.6 ng/dl at the time of NEPC diagnosis. All patients were treated with antiandrogen therapy and 87.5% with chemotherapy. A total of 273 lesions were identified by CT from which 182 were detected by 18 F-FDG PET/CT, 174 lesions by 18 F PSMA-1007, and 59 by 18 F AlF-NOTA-Octreotide. An interpatient analysis of the lesions was performed and dual tracer 18 F-FDG PET/CT and 18 F PSMA-1007 PET/CT detected a total of 270/273 lesions (98.9%). (3) Conclusions: NEDPC patients demonstrated wide inter and intrapatient molecular imaging heterogeneity within the three radiotracers. 18 F-FDG detected most lesions in t-NEPC among all radiotracers, especially in visceral sites; 18 F PSMA-1007 detected more bone lesions. 18 F AlF-NOTA-Octreotide showed no significant utility. |
